Watson Pharmaceuticals launches generic Biaxin

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Jan 4 2008

Watson Pharmaceuticals, Inc. has announced it has launched Clarithromycin Extended-Release Tablets, USP in the 500 mg strength.

Watson's Clarithromycin Extended-Release product is the generic equivalent to Abbott's Biaxin(R) XL, which is indicated to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. For the 12-months ending September 2007, Biaxin(R) XL and its generic equivalents had total U.S. sales of approximately $200 million, according to IMS Health data.

The U.S. Food and Drug Administration granted final approval of Watson's Abbreviated New Drug Application (ANDA) for Clarithromycin Extended-Release on June 24, 2004. Patent infringement litigation related to Watson's ANDA was dismissed with prejudice on July 12, 2007.

Source:

http://www.watsonpharm.com/

Posted in: Pharmaceutical News

Tags: , , , , ,

Comments (0)

Suggested Reading

RNA-based therapy shows promise in reducing cholesterol and triglycerides
St. Jude researchers unveil mechanisms to block PXR and enhance drug potency
Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation
Extended CPAP treatment boosts lung development in premature infants
Exercise-induced exerkines: Secret weapon in disease prevention and therapy
World's first human mini-brain with a fully functional blood-brain barrier developed
Lab to plant: Scaling up API processes with Dr. James Mencel's guidance
Study finds kidney complications following heart failure hospitalization

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics